Design, synthesis, cytotoxic evaluation and tubulin inhibitory activity of 4-aryl-5-(3,4,5-trimethoxyphenyl)-2-alkylthio-1H-imidazole derivatives. 2013

Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design & Development Research Center, Tehran University of Medical Sciences, Tehran 14176, Iran.

A new series of 4-aryl-5-(3,4,5-trimethoxyphenyl)-2-alkylthio-1H-imidazoles were synthesized and their cytotoxic activities in vitro against four different cell lines (HT-29, MCF-7, NIH-3T3, AGS) were evaluated. Compound 6g bearing 3,4,5-trimethoxyphenyl moiety on ring A and 4-methoxy substituent on ring B displayed potent cytotoxic activity against all cell lines. Flow cytometry analysis and microtubule polymerization assay confirmed that cytotoxic activities of this compound were related to inhibitory effect against microtubules polymerization. Molecular modeling studies revealed that compound 6g could strongly bind to the colchicine binding site of α,β-tubulin through hydrogen bond interactions with Thrα179 and Cysβ241.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008870 Microtubules Slender, cylindrical filaments found in the cytoskeleton of plant and animal cells. They are composed of the protein TUBULIN and are influenced by TUBULIN MODULATORS. Microtubule
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D050257 Tubulin Modulators Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. Microtubule Modulator,Tubulin Inhibitor,Tubulin Modulator,Tubulin Polymerization Inhibitor,Tubulin Polymerization Promoter,Tubulin Promoter,Microtubule Modulators,Tubulin Inhibitors,Tubulin Polymerization Inhibitors,Tubulin Polymerization Promoters,Tubulin Promoters,Inhibitor, Tubulin,Inhibitor, Tubulin Polymerization,Inhibitors, Tubulin,Inhibitors, Tubulin Polymerization,Modulator, Microtubule,Modulator, Tubulin,Modulators, Microtubule,Modulators, Tubulin,Polymerization Inhibitor, Tubulin,Polymerization Inhibitors, Tubulin,Polymerization Promoter, Tubulin,Polymerization Promoters, Tubulin,Promoter, Tubulin,Promoter, Tubulin Polymerization,Promoters, Tubulin,Promoters, Tubulin Polymerization

Related Publications

Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
August 2018, European journal of medicinal chemistry,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
August 2013, Molecular diversity,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
December 2021, European journal of medicinal chemistry,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
February 2017, Chemistry & biodiversity,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
January 2020, Bioorganic chemistry,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
May 2016, Scientific reports,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
August 2011, Bioorganic & medicinal chemistry,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
June 2007, Bioorganic & medicinal chemistry,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
September 2014, Archiv der Pharmazie,
Amir Assadieskandar, and Mohsen Amini, and Seyed Nasser Ostad, and Gholam Hossein Riazi, and Tayebe Cheraghi-Shavi, and Bentolhoda Shafiei, and Abbas Shafiee
August 2007, Acta pharmacologica Sinica,
Copied contents to your clipboard!